|Year : 2021 | Volume
| Issue : 1 | Page : 113-116
Oligometastasis to testis in prostate cancer: Role of gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography
Manoj Gupta1, Partha Sarathi Choudhury1, Sudhir Rawal2, Amitabh Singh2
1 Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
2 Department of Uro-Gynae Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
|Date of Submission||30-Mar-2020|
|Date of Decision||03-May-2020|
|Date of Acceptance||21-May-2020|
|Date of Web Publication||22-Aug-2020|
Dr. Manoj Gupta
Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, New Delhi - 110 085
| Abstract|| |
Accurate staging and restaging with early detection of recurrent site is the key for planning treatment in patients of prostate cancer. Recently, gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography (68Ga-PSMA PET/CT) has emerged as a better tool for this. Few uncommon sites of early metastasis can also be identified in addition to the other common sites. Herein, we present three cases of early metastasis to testis in prostate cancer identified on68Ga-PSMA PET/CT scan.
Keywords: Gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography, oligometastasis, prostate cancer, testicular metastasis
|How to cite this article:|
Gupta M, Choudhury PS, Rawal S, Singh A. Oligometastasis to testis in prostate cancer: Role of gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography. World J Nucl Med 2021;20:113-6
|How to cite this URL:|
Gupta M, Choudhury PS, Rawal S, Singh A. Oligometastasis to testis in prostate cancer: Role of gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography. World J Nucl Med [serial online] 2021 [cited 2021 Mar 5];20:113-6. Available from: http://www.wjnm.org/text.asp?2021/20/1/113/292976
| Introduction|| |
Prostate cancer is the second common cancer and the third leading cause of cancer-related deaths in men. Accurate staging and restaging with early detection of recurrence is the key for planning treatment. With the availability of gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography (68Ga-PSMA PET/CT) and better lymph node staging, early identification of metastatic or recurrent sites has been documented in recent time in the literature. With this prostate cancer-specific molecular imaging, we are not only able to identify metastatic sites early, but also can detect few uncommon sites. Here, we present three cases of metastatic disease involving testis in prostate cancer.
| Method|| |
On analysis of 186068Ga-PSMA PET/CT scans which were done for various clinical indications from July 2014 to February 2020, we identified three patients with oligometastasis to the testis [Table 1]. In-house synthesis of68Ga-PSMA-11 was done as per company-specific protocol in IQS-Fluidic labeling module (iTG) using PSMA peptide GMP kits from advanced biochemical compounds (ABx, GmbH, Germany). 2 MBq/kg body weight of68Ga-PSMA was injected intravenously, and the patients were rested for 1 h in an isolation room. Plain water was allowed during the uptake period. A whole-body scan was performed on a dedicated full-ring hybrid PET-CT system (Biograph TruePoint40 with LSO crystal from Siemens Healthcare, USA) with 4 min/bed position starting from the base of the skull to the midthigh. A noncontrast-enhanced CT scan (100 mAs and 120 kVp) was used for attenuation correction and anatomical interpretation.
| Case Reports|| |
A 62-year-old male was diagnosed with prostate cancer in July 2013. His initial prostate-specific antigen (PSA) was 11.5 ng/ml, and bone scan was normal. He underwent high-intensity focused ultrasound and channel transurethral resection of prostate (TURP). Microscopic examination of channel TURP chips showed prostatic acinar adenocarcinoma and Gleason score of 9 (4 + 5). He was started on hormone therapy (goserelin acetate). His PSA reduced up to 0.102 ng/ml. On follow-up, he presented with hematuria and difficulty in passing urine in February 2017. His PSA level was 13.2 ng/ml. A68Ga-PSMA PET/CT was performed which revealed PSMA-avid lesion in the prostate with infiltration in the bilateral seminal vesicles, posterior urinary bladder wall, and anterior rectal wall (maximum standardized uptake value [SUVmax] 8.9). Focal PSMA uptake was also noticed in the right testis (SUVmax 10.4) and fifth lumbar vertebra [Figure 1]. Ultrasound of the scrotum showed a hypoechoic lesion in the right testis with internal vascularity [Figure 1]. The patient underwent bilateral orchiectomy, and the final histopathology confirmed right testicular metastasis. The left testis and epididymis were free of tumor. He was further treated with antiandrogen (bicalutamide) and developed disease progression within 12 months.
|Figure 1: Gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography maximum intensity projection (a), fused coronal (b) and fused axial (c) images. Images showed prostate-specific membrane antigen-avid lesions in the prostate and right testis. A correlative ultrasonography of the scrotum showing a hypoechoic lesion in the right testis (d)|
Click here to view
A 77-year-old male was recently diagnosed with prostate cancer with a Gleason score of 9 (5 + 4) and PSA level of 79.38 ng/ml. A pelvic contrast magnetic resonance imaging revealed prostate lesion with the involvement of the bilateral seminal vesicles and bladder neck. Bone scan was normal. In view of high PSA level, he was referred for68Ga-PSMA PET/CT to look for any site of metastasis. PET/CT scan revealed PSMA-avid prostate lesion involving bilateral seminal vesicles (SUVmax 57.0), a right external iliac lymph node (size 1.0 cm × 0.9 cm, SUVmax 14.4), and focal PSMA uptake in the right testis (SUVmax 12.8) [Figure 2]. A mild focal PSMA uptake was also seen in the right iliac bone (SUVmax 3.2). In view of oligometastasis with locally advanced disease, the patient was started on hormone treatment.
|Figure 2: Gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography maximum intensity projection (a), fused coronal (b) and fused axial (c) images. Images showing prostate-specific membrane antigen-avid lesions in the prostate, right pelvic lymph node, and right testis|
Click here to view
A 69-year-old male, diagnosed with prostate cancer, underwent open radical prostatectomy in October 2012. Histopathology was prostatic acinar adenocarcinoma Gleason score of 7 (4 + 3) with pelvic lymph node metastasis (pT3bN1). Subsequently, he was treated with hormone (goserelin acetate). On follow-up, his PSA started rising and reached to 0.456 ng/ml in September 2017.68Ga-PSMA PET/CT scan showed mild PSMA-avid thickening in the prostatic bed and a subcentimeter left external iliac lymph node (SUVmax 2.5). In view of biochemical recurrence, he was further treated with image-guided radiotherapy, and post therapy, his PSA reduced to 0.076 ng/ml. On follow-up, he again presented with raised PSA 3.0 ng/ml in February 2020.68Ga-PSMA PET/CT revealed focal PSMA-avid (SUVmax 24.2) lesion in the left testis [Figure 3]. Ultrasound of the scrotum showed a hypoechoic lesion in the left testis [Figure 3]. He was advised for bilateral orchiectomy, however the patient refused to undergo surgery. He was started on hormone treatment.
|Figure 3: Gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography maximum intensity projection (a), fused coronal (b) and fused axial (c) images. Images showing a prostate-specific membrane antigen-avid lesion in the left testis. A correlative ultrasonography of the scrotum showing a hypoechoic lesion in the left testis (d)|
Click here to view
| Discussion|| |
Testicular metastasis is an uncommon event and constitutes 0.02%–2.5% of all testicular malignancies. It is most commonly associated with prostate cancer (35.4%), followed by lung (19.7%), melanoma (9.4%), and colon (8.7%) cancers. In general, it is associated with multiple sites of metastases and asymptomatic at presentation. Testicular metastasis has been diagnosed in 2%–4% of bilateral orchiectomy specimens in prostate cancer patients done for hormone control. Various routes of testicular metastasis from prostate cancer have been considered, which include retrograde vein spreading or embolization, arterial embolization, and lymphatic or endocanalicular spread. Unilateral testicular involvement with laterality toward the left side has been reported in a recent autopsy study on 738 adult males with solid malignant neoplasm. Even in prostate cancer, a preference toward left testicular metastasis has been reported in literature. This favoritism may be attributed to the location of the primary tumor in the prostate or may be just by chance or attributed to an unidentified reason. In paradox to that, in our three cases, two were involving the right testis. We are not able to identify any cause of this favoritism as in our cases both lobes of the prostate were involved by the tumor. A high Gleason score (≥7) has been attributed to testicular metastasis, which is in line with our case series as well. This may indicate the aggressiveness of the primary tumor for metastasis as such. On literature search, we identified four cases of testicular oligometastasis reported on68Ga-PSMA PET/CT scan.,,, All these cases identified testicular metastasis following biochemical relapse. In one of our cases, testicular metastasis was also diagnosed at staging workup. However, histopathology was not available in two of our cases due to nonsurgical treatment plan.
| Conclusions|| |
We believe that the novel imaging68Ga-PSMA PET/CT will further improve staging and restaging of prostate cancer. Recognizing testis as noncustomary site of metastasis will impact treatment planning and may also impact patient outcome.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
We would like to thank Dr. Syed Mohd Tauheed Alvi for helping in identifying the cases.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Haupt HM, Mann RB, Trump DL, Abeloff MD. Metastatic carcinoma involving the testis. Clinical and pathologic distinction from primary testicular neoplasms. Cancer 1984;54:709-14.
Baykal K, Yildirim S, Inal H, Kalci E, Albayrak S, Cingil H, et al
. Metastasis of prostate adenocarcinoma to testis. Int J Urol 1997;4:104-5.
García-González R, Pinto J, Val-Bernal JF. Testicular metastases from solid tumors: An autopsy study. Ann Diagn Pathol 2000;4:59-64.
Abou Heidar NF, Bustros G, El-Asmar JM, Sabatto BZ, Degheili JA. Isolated testicular metastasis diagnosed more than a decade and a half post primary treatment for prostate cancer. Case Rep Oncol Med 2019;2019:4956954.
Weiberg D, Radner H, Derlin T, Thon WF. Early detection of bilateral testicular metastases from prostatic adenocarcinoma using 68Ga-PSMA ligand PET/CT. Clin Nucl Med 2017;42:563-4.
da Cunha ML, de Oliveira Rodrigues C, de Araújo MP, de Freitas Junior CH, Ferrigno R. Solitary testicular metastasis from prostate cancer. A case report diagnosed by PET/CT with PSMA. Eur J Nucl Med Mol Imaging 2018;45:888-9.
Deeb IA, Khdhir MA, Bulbul M, Haidar M. Solitary metastasis of prostatic adenocarcinoma to the testicle detected by 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography. Indian J Nucl Med 2020;35:61-2.
] [Full text]
[Figure 1], [Figure 2], [Figure 3]